Market View 22nd September 2023

View on market: Volatility Prevails, Market is searching for better value

After American equities saw their largest decline in six months, equity markets in Asia are expected to gap lower. Futures for the Australian, Hong Kong, and Japanese indexes also indicated drops, adding to weekly losses. On Thursday, all significant U.S. market benchmarks went below their crucial 100-day moving averages as the S&P 500 dropped 1.6%, the biggest since March. Brent crude is currently trading at $93.25 per barrel. As of 6:10 am, the Gift Nifty was down 0.31% at 19,711.5.

Economic Calendar:

• USD : Services PMI (Sep) on 22^nd Sep, 2023
• USD : Building Permits on 26^th Sep, 2023
• INR : FX Reserves, USD on 22^nd Sep, 2023
• INR : Infrastructure Output (YoY) (Aug) on 29^th Sep, 2023

Brokerage Radar:

UBS ON INDUSIND BANK: Buy, TP Rs 1800; CEO meet takeaways; Focus remains on liability mix change and retail loans growth; Business growth on track (~18-22%); Margin to remain stable ~4.2-4.3%; Fall in specific credit cost likely needed for next leg of re-rating

MS ON SBI CARDS: OW, TP Rs 1155; Management meet takeaways; Spending growth trending well ahead of festive season; Share of interest-bearing assets continues to rise; Expects NIM to be stable to slightly lower in 2QF24; Guides for F24 operating cost to income ratio of 58-60%

CITI ON MARUTI: Buy, TP raised to Rs 13600; Even As Car Sales Remain Sluggish, An Improving Mix (Higher Proportion of UVs) Augurs Well for Earnings; Recent trends in product-mix bolster +ve stance

International Markets

U.S & Europe:

Asian markets:

ADR Watch:

Commodities & Currency:

FIIs & DIIs:

News Update:

Glenmark Pharmaceuticals: The global pharmaceutical company has entered into a definitive agreement with Nirma to divest a 75% stake in its subsidiary, Glenmark Life Sciences (GLS). The firm will sell the stake for Rs 5,651.5 crore, at the price of Rs 615 per share. Post the stake sale, Glenmark Pharma will own a 7.84% share in GLS and Nirma will then make a mandatory open offer to all public shareholders of GLS.

ICICI Bank: The country’s second-largest private sector lender has entered into an agreement for the investment of nearly Rs 5 crore in Quantum CorpHealth, which is a healthcare services platform. The transaction will be executed through equity shares and compulsorily convertible preference shares (CCPS). Post investment, the bank will hold 9.99% shareholding in Quantum CorpHealth through the subscription of 100 equity shares and 3,33,200 CCPS.

Vedanta: The mining company has received board approval for raising upto Rs 2,500 crore via non-convertible debentures (NCDs), in one or more tranche(s), on a private placement basis.

Zuari Industries: The company announced that its board of directors would consider the proposal of raising of funds on September 26. The fund raising will take place via the issuance of non-convertible debentures (NCDs), on a private placement basis.

InterGlobe Aviation: IndiGo and British Airways have signed a codeshare agreement to further boost the connections between India and the UK. With this codeshare partnership with IndiGo, British Airways will now be able to add three additional routes to their existing network.

Tech Mahindra: The IT solutions company has approved the merger of Tech Mahindra Credit Solutions Inc with its parent company Tech Mahindra (Americas) Inc. Tech Mahindra (Americas) Inc. is a wholly owned material subsidiary of Tech Mahindra. This merger of the two entities will optimise operational cost and reduce the compliance risk.

SJVN: The Government of India will exercise its greenshoe option of 2.46% stake or 9,66,72,961 shares for the offer-for-sale of the hydroelectric power generation company on September 22. This comes given the oversubscription in the issue, which is in addition to the base issue size of 9,66,72,961 shares or 2.46% stake. Hence, the total offer size will be up to 19,33,45,923 equity shares, representing 4.92% of the total paid up equity.

Infosys: The company will offer its Finacle Digital Banking Suite- Infosys Finacle, a part of EdgeVerve Systems, to Nigeria’s Guaranty Trust Bank which is the banking subsidiary of Guaranty Trust Holding Company Plc. Guaranty Trust Bank will use Infosys Finacle for its multi-country digital transformation program

Source: Moneycontrol, Bloomberg Quint, Investing 

Disclosure in pursuance of Section 19 of SEBI (RA) Regulation 2014

Elite Wealth Limited does/does not do business with companies covered in its research reports. Investors should be aware that the Elite Wealth Limited may/may not have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only information in making their investment decision and must exercise their own judgment before making any investment decision.

For analyst certification and other important disclosures, see the Disclosure Appendix, or go to www.elitewealth.in. Analysts employed by Elite Wealth Limited are registered/qualified as research analysts with SEBI in India.( SEBI Registration No.: INH100002300)

Disclosure Appendix

Analyst Certification (For Reports)

Kiran Tahlani, Elite Wealth Limited, kirantahlani@elitestock.com

The analyst(s) certify that all of the views expressed in this report accurately reflect my/our personal views about the subject company or companies and its or their securities. I/We also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Elite Wealth Limited.

As to each individual report referenced herein, the primary research analyst(s) named within the report individually certify, with respect to each security or issuer that the analyst covered in the report, that:

(1) all of the views expressed in the report accurately reflect his or her personal views about any and all of the subject securities or issuers; and

(2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed in the report.

For individual analyst certifications, please refer to the disclosure section at the end of the attached individual notes.

Research Excerpts

This note may include excerpts from previously published research. For access to the full reports, including analyst certification and important disclosures, investment thesis, valuation methodology, and risks to rating and price targets, please visit www.elitewealth.in.

Company-Specific Disclosures

Important disclosures, including price charts, are available and all Elite Wealth Limited covered companies by visiting https://www.elitewealth.in, or e-mailing research@elitestock.com with your request. Elite Wealth Limited may screen companies based on Strategy, Technical, and Quantitative Research. For important disclosures for these companies, please e-mail research@elitestock.com.

Options related research:

If the information contained herein regards options related research, such information is available only to persons who have received the proper option risk disclosure documents. For a copy of the risk disclosure documents, please contact your Broker’s Representative or visit the OCC’s website at https://www.elitewealth.in

Other Disclosures

All research reports made available to clients are simultaneously available on our client websites. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research reports available on a particular stock, please contact your respective broker’s sales person.

Ownership and material conflicts of interest Disclosure

Elite Wealth Limited policy prohibits its analysts, professionals reporting to analysts from owning securities of any company in the analyst’s area of coverage. Analyst compensation: Analysts are salary based permanent employees of Elite Wealth Limited. Analyst as officer or director: Elite Wealth Limited policy prohibits its analysts, persons reporting to analysts from serving as an officer, director, board member or employee of any company in the analyst’s area of coverage.

Country Specific Disclosures

India – For private circulation only, not for sale.

Legal Entities Disclosures

Mr. Ravinder Parkash Seth is the Managing Director of Elite Wealth  Ltd (EWL, henceforth), having its registered office at Casa Picasso, Golf Course Extension, Near Rajesh Pilot Chowk, Radha Swami, Sector-61, Gurgaon-122001 Haryana, is a SEBI registered Research Analyst and is regulated by Securities and Exchange Board of India. Telephone: 011-43035555, Facsimile: 011-22795783 and Website: www.elitewealth.in

EWL discloses all material information about itself including its business activity, disciplinary history, the terms and conditions on which it offers research report, details of associates and such other information as is necessary to take an investment decision, including the following:

1. Reports
2. a) EWL or his associate or his relative has no financial interest in the subject company and the nature of such financial interest;

(b) EWL or its associates or relatives, have no actual/beneficial ownership of one per cent. or more in the securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance;

(c) EWL or its associate or his relative, has no other material conflict of interest at the time of publication of the research report or at the time of public appearance;

2. Compensation

(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;

(b) EWL or its associates have not managed or co-managed public offering of securities for the subject company in the past twelve months;

(c) EWL or its associates have not received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months;

(d) EWL  or its associates have not received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months;

(e) EWL or its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.

3 In respect of Public Appearances
(a) EWL or its associates have not received any compensation from the subject company in the past twelve months;
(b) The subject company is not now or never a client during twelve months preceding the date of distribution of the research report and the types of services provided by EWL

Provided that research analyst or research entity shall not be required to make a disclosure as per sub-clauses (c), (d) and (e) of clause (ii) or sub-clauses (a) and (b) of clause (iii) to the extent such disclosure would reveal material non-public information regarding specific potential future investment banking or merchant banking or brokerage services transactions of the subject company.
(4) EWL or its proprietor has never served as an officer, director or employee of the subject company;
(5) EWL has never been engaged in market making activity for the subject company;
(6) EWL shall provide all other disclosures in research report and public appearance as specified by the Board under any other regulations